Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press1110.17650/2313-805X.2014.1.1.5-11REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИMultidrug resistance of tumor cells: some new trends in researchНекоторые новые аспекты исследований множественной лекарственной устойчивости опухолевых клетокStavrovskayaA. A.СтавровскаяА. А.
Russian Federation
astavrovskaya@yahoo.comGuensG. P.ГенсГ. П.
Russian Federation
Federal State Budgetary Institution “N. N. Blokhin Russiаn Cancer Research Center”, Russian Academy of Medical Sciences, MoscowФГБУ «Российский онкологический научный центр им. Н. Н. Блохина» РАМН, МоскваDepartment of Oncology and Radiology, Evdokimov State University of Medicine and Dentistry, Moscowкафедра онкологии и лучевой терапии ГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России15012014115110206201502062015Copyright ©; 2014, Stavrovskaya A.A., Guens G.P.Copyright ©; 2014, Ставровская А.А., Генс Г.П.2014Stavrovskaya A.A., Guens G.P.Ставровская А.А., Генс Г.П.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/11

Multidrug resistance (MDR) of tumor cells is the resistance to a broad spectrum of structurally unrelated cytotoxic drugs with different mechanisms of action. One of the main causes of MDR phenotype is the activity of ATP-binding cassette transporters (ABC transporters). ABC transporters efflux toxic compounds from the cells. All living cells contain ABC transporters. This review is dedicated to the studies of three-dimensional structure of ABC transporters, to the data concerning MDR evolution in tumor cell populations. Some information about molecular mechanisms of MDR evolution is also presented.

Множественная лекарственная устойчивость (МЛУ) опухолевых клеток – резистентность клетки одновременно к большому количеству веществ, разных по химическому строению и механизму действия. Одним из важнейших и наиболее исследованных механизмов МЛУ является активность транспортных белков семейства АВС (АВС-транспортеры). АВС-транспортеры, выводящие токсические соединения из клеток, и гены, кодирующие АВС-транспортеры, содержатся во всех живых клетках. В обзоре рассматриваются работы, посвященные исследованию трехмерной структуры АВС-транспортеров; результаты, полученные при изучении эволюции МЛУ, определяемой АВС-транспортерами, а также некоторые молекулярные механизмы, которые могут определять эволюцию МЛУ.

multidrug resistanceАВС-transporterstumor stem cellsepithelial-mesenchymal transitionYB-1 proteinмножественная лекарственная устойчивостьАВС-транспортерыстволовые клетки опухолиэпителиально- мезенхимальный переходбелок YB-11. Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007;446(7137): 749–57.Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007;446(7137): 749–57.2. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361–98.Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361–98.3. Нейфах А.А. Множественная лекарственная устойчивость: решение проблемы? Биол мембраны 2003;20(3):206–12.Нейфах А.А. Множественная лекарственная устойчивость: решение проблемы? Биол мембраны 2003;20(3):206–12.4. Zheleznova E.E., Markham P.N., Neyfakh A.A., Brennan R.G. Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter. Cell 1999;9(3):353–62.Zheleznova E.E., Markham P.N., Neyfakh A.A., Brennan R.G. Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter. Cell 1999;9(3):353–62.5. Aller S.G., Yu J., Ward A. et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323(5922):1679–80.Aller S.G., Yu J., Ward A. et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323(5922):1679–80.6. Wen P.C., Verhalen B., Wilkens S. et al. Origin of large flexibility of P-glycoprotein in the inward-facing state. J Biol Chem 2013;288(26):19211–20.Wen P.C., Verhalen B., Wilkens S. et al. Origin of large flexibility of P-glycoprotein in the inward-facing state. J Biol Chem 2013;288(26):19211–20.7. Ni Z., Bikadi Z., Shuster D.L. et al. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ ABCG2) that are important for transport activity and substrate specificity. Biochemistry 2011;50(37):8057–66.Ni Z., Bikadi Z., Shuster D.L. et al. Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ ABCG2) that are important for transport activity and substrate specificity. Biochemistry 2011;50(37):8057–66.8. Li X., Lewis M.T., Huang J. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100(9):672–9.Li X., Lewis M.T., Huang J. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100(9):672–9.9. Стромская Т.П., Рыбалкина Е.Ю., Круглов С.С. и др. Участие Р-гликопротеина в эволюции популяций клеток хронического миелолейкоза при воздействии иматиниба. Биохимия 2008;73(1):36–46.Стромская Т.П., Рыбалкина Е.Ю., Круглов С.С. и др. Участие Р-гликопротеина в эволюции популяций клеток хронического миелолейкоза при воздействии иматиниба. Биохимия 2008;73(1):36–46.10. Calcagno A.M., Salcido C.D., Gillet J.-P. et al. Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. J Natl Cancer Inst 2010;102(21):1637–52.Calcagno A.M., Salcido C.D., Gillet J.-P. et al. Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. J Natl Cancer Inst 2010;102(21):1637–52.11. Панищева Л.А. Экспрессия и активность белков множественной лекарственной устойчивости опухолей при воздействии ингибитора протеасом бортезомиба. Автореф. дис. … канд. биол. наук. М., 2012.Панищева Л.А. Экспрессия и активность белков множественной лекарственной устойчивости опухолей при воздействии ингибитора протеасом бортезомиба. Автореф. дис. … канд. биол. наук. М., 2012.12. Панищева Л.А., Какпакова Е.С., Рыбалкина Е.Ю., Ставровская А.А. Влияние протеасомного ингибитора бортезомиба на экспрессию генов множественной лекарственной устойчивости и активность киназы Akt. Биохимия 2011;76(9):1238–47.Панищева Л.А., Какпакова Е.С., Рыбалкина Е.Ю., Ставровская А.А. Влияние протеасомного ингибитора бортезомиба на экспрессию генов множественной лекарственной устойчивости и активность киназы Akt. Биохимия 2011;76(9):1238–47.13. Saxena M., Stephens M.A., Pathak H., Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dif 2011;2:e179.Saxena M., Stephens M.A., Pathak H., Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dif 2011;2:e179.14. Pinto C.A., Widodo E., Waltham M., Thompson E.W. Breast cancer stem cells and epithelial mesenchymal plasticity – Implications for chemoresistance. Cancer Lett 2013. pii: S0304-3835(13)00453-9. oi:10.1016/j.canlet.2013.06.003. [Epub ahead of print].Pinto C.A., Widodo E., Waltham M., Thompson E.W. Breast cancer stem cells and epithelial mesenchymal plasticity – Implications for chemoresistance. Cancer Lett 2013. pii: S0304-3835(13)00453-9. oi:10.1016/j.canlet.2013.06.003. [Epub ahead of print].15. Mani S.A., Guo W., Liao M.J. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;13(4):704–15.Mani S.A., Guo W., Liao M.J. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;13(4):704–15.16. Clevers H. The cancer stem cell: remises, promises and challenges. Nat Med 2011;17(3):313–9.Clevers H. The cancer stem cell: remises, promises and challenges. Nat Med 2011;17(3):313–9.17. Francipane M.G., Chandler J., Lagasse E. Cancer Stem Cells: A Moving Target. Curr Pathobiol Rep 2013;1(2):111–8.Francipane M.G., Chandler J., Lagasse E. Cancer Stem Cells: A Moving Target. Curr Pathobiol Rep 2013;1(2):111–8.18. Chaudhary P.M., Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66(1):85–94.Chaudhary P.M., Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66(1):85–94.19. Kim M., Turnquist H., Jackson J. et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002;8(1):22–8.Kim M., Turnquist H., Jackson J. et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002;8(1):22–8.20. Scharenberg C.W., Harkey M.A., Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002;99(2):507–12.Scharenberg C.W., Harkey M.A., Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002;99(2):507–12.21. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009;14(1):3–9.Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009;14(1):3–9.22. de Grouw E.P., Raaijmakers M.H., Boezeman J.B. et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells. Leukemia 2006;20(4):750–4.de Grouw E.P., Raaijmakers M.H., Boezeman J.B. et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells. Leukemia 2006;20(4):750–4.23. Moitra K., Lou H., Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 2011;89(4):491–02.Moitra K., Lou H., Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 2011;89(4):491–02.24. Barbet R., Peiffer I., Hutchins J.R. et al. Expression of the 49 human ATP binding cassette (ABC) genes in pluripotent embryonic stem cells and in early- and late-stage multipotent mesenchymal stem cells: possible role of ABC plasma membrane transporters in maintaining human stem cell pluripotency. Cell Cycle 2012;11(8):1611–20.Barbet R., Peiffer I., Hutchins J.R. et al. Expression of the 49 human ATP binding cassette (ABC) genes in pluripotent embryonic stem cells and in early- and late-stage multipotent mesenchymal stem cells: possible role of ABC plasma membrane transporters in maintaining human stem cell pluripotency. Cell Cycle 2012;11(8):1611–20.25. Ставровская А.А. Множественная лекарственная устойчивость, обусловленная активностью транспортных белков клетки: новые факты и некоторые перспективы исследований. Биол мембраны 2003;20(3):196–205.Ставровская А.А. Множественная лекарственная устойчивость, обусловленная активностью транспортных белков клетки: новые факты и некоторые перспективы исследований. Биол мембраны 2003;20(3):196–205.26. Мечетнер Е.Б. Новые подходы к оценке экспрессии и функциональной активности Р-гликопротеина. Биол мембраны 2003;20( 3):213–24.Мечетнер Е.Б. Новые подходы к оценке экспрессии и функциональной активности Р-гликопротеина. Биол мембраны 2003;20( 3):213–24.27. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615–27.Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615–27.28. Frank N.Y., Pendse S.S., Lapchak P.H. et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 2003;278(47):47156–65.Frank N.Y., Pendse S.S., Lapchak P.H. et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 2003;278(47):47156–65.29. Frank N.Y., Margaryan A., Huang Y. et al. BCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65(10): 4320–33.Frank N.Y., Margaryan A., Huang Y. et al. BCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65(10): 4320–33.30. Schatton T., Murphy G.F., Frank N.Y. et al. Identification of cells initiating human melanomas. Nature 2008;451(7176):345–9.Schatton T., Murphy G.F., Frank N.Y. et al. Identification of cells initiating human melanomas. Nature 2008;451(7176):345–9.31. Cheung S.T., Cheung P.F., Cheng C.K. et al. Granulin-epithelin precursor and ATPdependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology 2011;140(3):344–55.Cheung S.T., Cheung P.F., Cheng C.K. et al. Granulin-epithelin precursor and ATPdependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. Gastroenterology 2011;140(3):344–55.32. Wilson B.J., Schatton T., Zhan Q. et al. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res 2011;71(15):5307–16.Wilson B.J., Schatton T., Zhan Q. et al. ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res 2011;71(15):5307–16.33. Zhou S., Morris J.J., Barnes Y. et al. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 2002;99(19): 12339–44.Zhou S., Morris J.J., Barnes Y. et al. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 2002;99(19): 12339–44.34. Schinkel A.H., Smit J.J., van Tellingen O. et al. Disruption of the mouse mdr1a P glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77(4):491–502.Schinkel A.H., Smit J.J., van Tellingen O. et al. Disruption of the mouse mdr1a P glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77(4):491–502.35. Sereti K.I., Oikonomopoulos A., Unno K. et al. ATP-binding cassette G-subfamily transporter 2 regulates cell cycle progression and asymmetric division in mouse cardiac side population progenitor cells. Circ Res 2013;112(1):27–34.Sereti K.I., Oikonomopoulos A., Unno K. et al. ATP-binding cassette G-subfamily transporter 2 regulates cell cycle progression and asymmetric division in mouse cardiac side population progenitor cells. Circ Res 2013;112(1):27–34.36. Ставровская А.А., Стромская Т.П. Транспортные белки семейства АВС и множественная лекарственная устойчивость опухолевых клеток (обзор). Биохимия 2008;73(5):735–50.Ставровская А.А., Стромская Т.П. Транспортные белки семейства АВС и множественная лекарственная устойчивость опухолевых клеток (обзор). Биохимия 2008;73(5):735–50.37. Sui H., Fan Z.Z., Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res 2012;40(2):426–35.Sui H., Fan Z.Z., Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res 2012;40(2):426–35.38. Елисеева И.А., Ким Е.Р., Гурьянов С.Г., Овчинников Л.П., Лябин Д.Н. Y-бокс-связывающий белок 1 (YB-1) и его функции. Биохимия 2011;13:1402–33.Елисеева И.А., Ким Е.Р., Гурьянов С.Г., Овчинников Л.П., Лябин Д.Н. Y-бокс-связывающий белок 1 (YB-1) и его функции. Биохимия 2011;13:1402–33.39. Bargou R.C., Jürchott K., Wagener C. et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3(4):447–50.Bargou R.C., Jürchott K., Wagener C. et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3(4):447–50.40. Saji H., Toi M., Saji S. et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett 2003;190(2):191–7.Saji H., Toi M., Saji S. et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett 2003;190(2):191–7.41. Janz M., Harbeck N., Dettmar P. et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002;97(3):278–82.Janz M., Harbeck N., Dettmar P. et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002;97(3):278–82.42. Oda Y., Sakamoto A., Shinohara N. et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 1998;4(9):2273–7.Oda Y., Sakamoto A., Shinohara N. et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 1998;4(9):2273–7.43. Shibahara K., Sugio K., Osaki T. et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001;7(10):3151–5.Shibahara K., Sugio K., Osaki T. et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001;7(10):3151–5.44. Stein U., Bergmann S., Scheffer G.L. et al. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene 2005;24(22):3606–18.Stein U., Bergmann S., Scheffer G.L. et al. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene 2005;24(22):3606–18.45. Geier A., Mertens P.R., Gerloff T. et al. Constitutive rat multidrug-resistance protein 2 gene transcription is down-regulated by Ybox protein 1. Biochem Biophys Res Commun 2003;309(3):612–8.Geier A., Mertens P.R., Gerloff T. et al. Constitutive rat multidrug-resistance protein 2 gene transcription is down-regulated by Ybox protein 1. Biochem Biophys Res Commun 2003;309(3):612–8.46. Vaiman A.V., Stromskaya T.P., Rybalkina E.Y. et al. Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells. Biochemistry (Mosc) 2006;71(2):146–54.Vaiman A.V., Stromskaya T.P., Rybalkina E.Y. et al. Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells. Biochemistry (Mosc) 2006;71(2):146–54.47. Kuwano M., Oda Y., Izumi H. et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004;3(11):1485–92.Kuwano M., Oda Y., Izumi H. et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004;3(11):1485–92.48. Woolley A.G., Algie M., Samuel W. et al. Prognostic association of YB-1 expression in breast cancers: a matter of antibody. PLoS One 2011;6(6): e20603.Woolley A.G., Algie M., Samuel W. et al. Prognostic association of YB-1 expression in breast cancers: a matter of antibody. PLoS One 2011;6(6): e20603.49. Stavrovskaya A., Stromskaya T., Rybalkina E. et al. YB-1 protein and multidrug resistance of tumor cells. Current Signal Trunsduction Therapy 2012;7(3):237–46.Stavrovskaya A., Stromskaya T., Rybalkina E. et al. YB-1 protein and multidrug resistance of tumor cells. Current Signal Trunsduction Therapy 2012;7(3):237–46.50. Lasham A., Print C.G., Woolley A.G. et al. YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J 2013;449(1):11–23.Lasham A., Print C.G., Woolley A.G. et al. YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J 2013;449(1):11–23.51. Генс Г.П., Моисеева Н.И., Стромская Т.П. и др. Определение количества мРНК гена YB-1 в тканях опухолей молочной железы с целью прогнозирования течения заболевания. Клиническая и лабораторная диагностика 2010;2:29–32.Генс Г.П., Моисеева Н.И., Стромская Т.П. и др. Определение количества мРНК гена YB-1 в тканях опухолей молочной железы с целью прогнозирования течения заболевания. Клиническая и лабораторная диагностика 2010;2:29–32.52. Frye B.C., Halfter S., Djudjaj S. et al. Y- box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep 2009;10(7):783–789.Frye B.C., Halfter S., Djudjaj S. et al. Y- box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep 2009;10(7):783–789.53. Rauen T., Raffetseder U., Frye B.C. et al. YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation. J Biol Chem 2009;284(39):26928–40.Rauen T., Raffetseder U., Frye B.C. et al. YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation. J Biol Chem 2009;284(39):26928–40.54. Моисеева Н.И., Стромская Т.П., Рыбалкина Е.Ю. и др. Влияние внеклеточного белка YB-1 на культивируемые клетки опухолей молочной железы. Биол мембраны 2012;29(5):1–9.Моисеева Н.И., Стромская Т.П., Рыбалкина Е.Ю. и др. Влияние внеклеточного белка YB-1 на культивируемые клетки опухолей молочной железы. Биол мембраны 2012;29(5):1–9.